Advertisement


Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia

2018 ASCO Annual Meeting

Advertisement

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macroglobulinemia (Abstract 8003).



Related Videos

Gynecologic Cancers
Immunotherapy

Robert L. Coleman, MD, on Ovarian Cancer: Results From an NRG Oncology/Gynecologic Oncology Group Trial

Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on secondary surgical cytoreduction followed by platinum-based combination chemotherapy, with or without bevacizumab, in platinum-sensitive, recurrent ovarian cancer (Abstract 5501).

Breast Cancer

Sherry Shen, MD, on Breast Cancer and Obesity: Results of the SWOG S0927 Study

Sherry Shen, MD, of Columbia University Medical Center, discusses findings on the use of omega-3 fatty acid for obese breast cancer patients with aromatase inhibitor–related arthralgia (Abstract 10000).

Breast Cancer

Joseph A. Sparano, MD, on Breast Cancer: Results of the TAILORx Trial

Joseph A. Sparano, MD, of Montefiore Medical Center, discusses phase III study results on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score (Abstract LBA1).

Prostate Cancer

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, on Prostate Cancer: Results of the SPCG-13 Trial

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Elizabeth R. Plimack, MD, on RCC: Perspectives on KEYNOTE-427 and IMmotion151

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented in renal cell cancer.

Advertisement

Advertisement




Advertisement